PMPRB Summary of VCUs & Orders - 1996 - 2002
Click on medicine to view details of VCU
| DATE OF APPROVAL |
MEDICINE |
PATENTEE |
%Above Guidelines |
PRICE REDUCTION1 |
EXCESS REVENUES2 |
PAYMENTS |
PATENT STATUS |
| VCUs |
| Sept. 16, 2002 |
Differin Pledget |
Galderma Canada Inc. |
34.5 |
Yes |
$17,575.12 |
$17,575.12 |
|
| October 15, 2001 |
Zanaflex |
Draxis Health Inc. |
10.5 - 7.6 |
Yes |
$62,559 |
$62,559 |
|
| June 30, 2000 |
Plavix |
Bristol-Myers Squibb/Sanofi |
|
Yes - $2,40/tablet |
|
$583,065 |
Expired 10/2002; 08/2012 |
| August 11, 1999 |
Anaprox |
Hoffmann-La Roche Limited |
0.02 - 1.39 |
Yes - $0.58 |
$67,252.55 |
$67,252.55 |
|
| April 29, 1998 |
Humalog |
Eli Lilly Canada Inc. |
23 |
Yes - $22.11 |
$666,824 |
$666,824 |
|
| March 5, 1996 |
Prostep |
Boehringer Ingelheim |
12 - 15 |
Yes - $3.20/$3.28/patch |
$14,959 |
$14,959 |
|
| ORDER |
| Jul. 26, 1996 |
Virazole |
ICN Canada Ltd. |
342 |
Yes - Approx. $200/vial |
$3,460,01415 |
$1,200,000 |
|
1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.
2. In all cases, all excess revenues were offset through further price reduction and/or payment.
15. The order required ICN to offset double the excess revenues it had received of $1.7M. See Board's Variation Order of March 29, 2000.